Mode
Text Size
Log in / Sign up

Shorter DAPT after PCI raises modeled MI odds; 1-month step not supportedFinding the safest time to stop aspirin for heart patients after surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret short DAPT MI thresholds cautiously; estimates are model-dependent and certainty is low.

This is a Bayesian model-based dose-response network meta-analysis of randomized trials, pooling 16 trials and 17 randomized comparisons covering 58,068 patients undergoing PCI in whom aspirin was withdrawn and a P2Y12 inhibitor continued. The prespecified estimand was the shortest DAPT duration at which the upper 95% credible limit of the MI odds ratio versus 12-month DAPT fell below 1.15.

Across 929 modeled MIs, the odds ratio versus 12-month DAPT was 1.31 at 0 days (95% credible interval 0.95-2.09), 1.17 at 30 days (0.96-1.43), and 1.09 at 90 days (0.98-1.25). The point estimate exceeded 1.15 below about 3 weeks and fell below it from about 90 days. A 30-day change-point did not fit better than a smooth curve.

The duration meeting the prespecified estimand differed by model: 158 days with an Emax model and 282 days with a spline model. For bleeding, based on 1,102 major bleeding events, odds ratios were 0.40 at 0 days and 0.62 at 90 days, indicating lower bleeding odds with shorter DAPT.

Authors graded certainty as low for MI below 90 days and for the estimand, and moderate for bleeding. Follow-up duration, funding, and conflicts were not reported. The modeled curves suggest matching DAPT duration to ischemic risk rather than applying a fixed early step, but the threshold estimates are model-dependent and should not be read as definitive.

How this fits prior evidence

Prior coverage noted that antiplatelet monotherapy after ultrashort DAPT showed no statistically significant difference in major bleeding or MACE. This modeling analysis extends that question by treating DAPT duration as continuous rather than as a single early-versus-standard contrast, and it reports higher modeled MI odds at very short durations alongside lower bleeding odds. It also argues against a discrete 30-day change-point, which a 30-day change-point analysis did not support. The findings are consistent with the broader theme in prior coverage that antiplatelet strategies after PCI trade ischemic and bleeding risk, but certainty for MI below 90 days remains low.

Patients who have heart issues and undergo a procedure to open blocked arteries often take two types of blood thinners. One is a drug called a P2Y12 inhibitor, and the other is aspirin. Doctors need to decide how long a patient should stay on both medicines before stopping the aspirin.

Stopping aspirin too early can increase the risk of a heart attack. However, staying on both drugs for too long can lead to dangerous bleeding. This study looked at over 58,000 patients to find the safest window for switching to a single medication.

Researchers found that the risk of a heart attack dropped significantly as the time on both drugs increased. Specifically, the risk became much lower after about 90 days. At the same time, the risk of serious bleeding dropped when patients stopped taking aspirin sooner.

While the exact number of days to stop aspirin can vary depending on the math model used, the data suggests a safer balance is found after several months. Doctors can use these findings to help decide the best timing for each individual patient's care plan.

What this means for you:
Stopping aspirin after about 90 days can lower bleeding risks while keeping heart attack risks at a safe level.

Common questions

How much does shorter aspirin use raise heart attack risk after a stent?

In the pooled analysis, the odds ratio for heart attack versus 12 months of dual therapy was 1.31 at 0 days, 1.17 at 30 days, and 1.09 at 90 days. There were 929 heart attacks in total. Certainty was low for heart attack results below 90 days, so these are estimates, not fixed risks for any one person.

Does stopping aspirin early lower bleeding risk?

Yes, the analysis found major bleeding was less common with shorter dual therapy. The odds ratio for major bleeding was 0.40 at 0 days and 0.62 at 90 days, based on 1,102 major bleeding events. Certainty for bleeding was moderate. Your own bleeding and clotting risks depend on your health history, so discuss them with your doctor.

What is the shortest safe duration of dual antiplatelet therapy?

The analysis could not settle on one number. The shortest duration meeting the researchers' preset threshold was 158 days in one model and 282 days in another. A 30-day cutoff did not fit the data better. Because the models disagree and certainty was low, these figures should not be treated as a firm rule.

Should I stop aspirin after my stent?

This analysis does not give personal advice, and the decision depends on your heart attack risk, bleeding risk, and stent type. The findings suggest shorter aspirin use trades less bleeding for somewhat higher heart attack odds. Talk with your cardiologist before making any change to your antiplatelet medicines.

Study Details

Study typeMeta analysis
Sample sizen = 58,068
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Background: Trials of P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI) withdrew aspirin at fixed times, mostly against 12-month dual antiplatelet therapy (DAPT), and categorical syntheses disagree. Methods: Bayesian model-based network meta-analysis of randomized trials of aspirin withdrawal with P2Y12 inhibitor continuation, with 12-month myocardial infarction (MI) and major bleeding modeled as functions of DAPT duration (Emax and spline). The prespecified estimand was the shortest duration at which the upper 95% credible limit of the odds ratio (OR) for MI versus 12-month DAPT fell below 1.15. Results: Sixteen trials (17 randomized comparisons, 58,068 patients) contributed 929 MIs and 1,102 major bleeding events. The OR for MI was 1.31 (95% credible interval 0.95-2.09) at 0 days, 1.17 (0.96-1.43) at 30 days, and 1.09 (0.98-1.25) at 90 days. Under every model the point estimate exceeded 1.15 below about 3 weeks and fell below it from about 90 days; a 30-day change-point did not fit better. The credible bound was met at 158 days (Emax) and 282 days (spline). Bleeding decreased with shorter duration (OR 0.40 at 0 days, 0.62 at 90 days). Certainty was low for MI below 90 days and the estimand, moderate for bleeding. Conclusions: Shorter DAPT reduced major bleeding, and the ischemic cost of aspirin withdrawal declined with duration; a step at 1 month was not supported. A 15% excess of MI could be excluded from about 5 months (Emax) or 9 months (spline). The curves match duration to each patient's ischemic margin.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.